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Absfract: The present investigation was conducted to evaluate the predictive value of 
bone marrow examination for myelotoxicity after cytotoxic chemotherapy. A total of 25 
patients with urogenital cancer underwent bone marrow examination in the Department of 
Urology， Nara Medical University and its affiliated hospitals between August 1989 and 
September 1991. Those parameters including myeloid counts before chemotherapy(M 
Number)， reticulocyte counts before chemotherapy(Ret)， WBC counts before chemother-
apy(WBC)and at nadir(N-WBC)， interval of the beginning of chemotherapy and nadir(N 
-Day)， interval of recovering days from nadir (R -Day) and N + R -Day were examined. A 
significant relationship between M-Number and WBC was observed(r=0.367， p=0.016). 
A negative relationship between WBC and N-Day was observed(r二一0.257，p=0.097). 
There were also negative relationships between Ret and R-Day(r= -0.337， p二 0.068)and
between WBC and R-Day(r= -0.254， p= 0.084). In addition， a negative relationship could 
be seen between WBC and N + R -Day(rニー0.306，p=0.06D. As for M-Number， however， 
no relationship with any other parameters concerned with myelotoxicity after chemother-
apy was found. Thus， bone marrow examination before cytotoxic chemotherapy did not 
show a predictive value for myelotoxicity after chemotherapy. 
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M -V AC(MTX + VLB+ DXR十CDDP)療法が 3例，





































1989年 7月より 1991年 9月までに，奈良県立医科大
学，県立奈良病院ならびに松阪中央病院泌尿器科にて入
院治療した尿路性器悪性腫蕩症例 25例を対象とした.内
















































Renal pelvic and/or 
Ureteral cancer 
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は， r=-0.337(p=0.068)， r二 0.254 (p = 0.084)と負
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